NCT04966871View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 27, 2021

Primary Completion Date

June 21, 2022

Study Completion Date

June 21, 2022

Conditions
Malaria
Interventions
BIOLOGICAL

PfSPZ Vaccine

Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)

BIOLOGICAL

PfSPZ Challenge (7G8) for CHMI

Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8

OTHER

Normal Saline

normal saline placebo control

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center, Seattle

All Listed Sponsors
collaborator

Fred Hutchinson Cancer Center

OTHER

lead

Sanaria Inc.

INDUSTRY

NCT04966871 - Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults | Biotech Hunter | Biotech Hunter